Evaluation of the effectiveness and safety of a controlled-release theophylline in patients with reversible and stable bronchial obstruction.
In this study the effectiveness and safety of a new controlled-release theophylline formulation were evaluated. Twenty patients (12 male, 8 female) affected by bronchial asthma (mean age 45 years) or chronic obstructive lung disease (mean age 58 years) were given the drug. During the 30 days of controlled-release theophylline therapy, all patients reported a marked clinical improvement, confirmed by spirometric data (ventilation indexes, intrapulmonary air distribution, ventilation control, gas exchanges). Tolerability was excellent.
Grassi
V
V
Chair of Respiratory Physiopathology, University of Perugia, Italy.
Nicora
M
M
Beretta
A
A
D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012119:Respiration / Q000187:drug effects; D013806:Theophylline / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood
D003692:Delayed-Action Preparations; D013806:Theophylline